RSS

antibody combination therapy (ACT) platform

RedHill Biopharma has announced dosing of the first patient in the open-label extension study to the Phase III study with RHB-104 for the treatment of Crohn’s disease. Read more

News

Catalent has signed an exclusive licencing agreement to access Excelimmune's antibody combination therapy technology platform, which has the potential to pave the way for more consistent, cost-effective production of antibody combinations. Read more

News